Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer

NCT07691593 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: HRS-4642+NALIRIFOX
DRUG: HRS-4642+NALIRIFOX+Adebrelimab
DRUG: HRS-4642+NALIRIFOX+Adebrelimab

Sponsor

Changhai Hospital